A6981

应用筛选条件

关键词:'A6981'

显示 1-8 共 8 条结果关于 "A6981" 范围论文

Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels.

Fan Xu et al.

Arzneimittel-Forschung, 59(12), 631-634 (2010-01-30)

To study the pharmacokinetics of acamprosate calcium (CAS 77337-73-6) in healthy Chinese subjects after oral administration of three dosage levels, 12 healthy subjects were divided into three groups and given a single oral dose of 333 or 666 or 1332

Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat.

Roberto Ciccocioppo et al.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(11), 2601-2610 (2014-05-28)

Since its discovery, the nociceptin/orphanin FQ (N/OFQ)-NOP receptor system has been extensively investigated as a promising target to treat alcoholism. Encouraging results obtained with the endogenous ligand N/OFQ stimulated research towards the development of novel brain-penetrating NOP receptor agonists with

Acamprosate Is a Substrate of the Human Organic Anion Transporter (OAT) 1 without OAT3 Inhibitory Properties: Implications for Renal Acamprosate Secretion and Drug-Drug Interactions.

Irina E Antonescu et al.

Pharmaceutics, 12(4) (2020-04-30)

Acamprosate is an anionic drug substance widely used in treating symptoms of alcohol withdrawal. It was recently shown that oral acamprosate absorption is likely due to paracellular transport. In contrast, little is known about the eliminating mechanism clearing acamprosate from

Acamprosate. A review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification.

M I Wilde et al.

Drugs, 53(6), 1038-1053 (1997-06-01)

Acamprosate (calcium acetylhomotaurinate), a synthetic compound with a similar chemical structure to that of gamma-aminobutyric acid, is thought to act via several mechanisms affecting multiple neurotransmitter systems; inhibition of neuronal hyperexcitability by antagonism of excitatory amino acid activity and reduction

Open-label trial of acamprosate as a treatment for anxiety.

Marc Hertzman et al.

Primary care companion to the Journal of clinical psychiatry, 11(5), 267-267 (2009-12-04)

Acamprosate calcium as augmentation therapy for anxiety disorders.

Thomas L Schwartz et al.

The Annals of pharmacotherapy, 44(12), 1930-1932 (2010-11-11)

Glutamate is a major excitatory neurotransmitter, while γ-aminobutyric acid (GABA) is a predominant inhibitory neurotransmitter in the central nervous system. This GABA-glutamate imbalance is thought to play a role in the development of anxiety. Acamprosate calcium is thought to restore

Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy.

Ilya Chumakov et al.

Scientific reports, 5, 7608-7608 (2015-01-09)

Alzheimer disease (AD) represents a major medical problem where mono-therapeutic interventions demonstrated only a limited efficacy so far. We explored the possibility of developing a combinational therapy that might prevent the degradation of neuronal and endothelial structures in this disease.

Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence

Baser, O., et al.

The American Journal of Managed Care, 8, S222-S234 (2011)

1/1